Absci (ABSI) drew fresh attention after Leerink initiated coverage, highlighting the company’s AI native, clinical stage drug pipeline, including ABS-20 and ABS-201, and pointing to 2026 as a potentially important clinical data year.

Absci’s recent coverage has coincided with strong momentum, with a 30 day share price return of 60.04% and a 90 day share price return of 150.34%. The 1 year total shareholder return of 169.45% points to strong longer term interest around the AI driven pipeline story.

If you are looking beyond Absci for other ways to position around AI in healthcare, this could be a good moment to scan the market using the 41 healthcare AI stocks

With Absci trading at $7.41 and sitting around 30% below the current analyst price target of $9.61, the key question is whether enthusiasm around its AI drug pipeline leaves upside on the table or whether markets are already pricing in future growth.

Most Popular Narrative: 63.3% Overvalued

On the most followed narrative, Absci’s fair value of $4.54 sits well below the last close at $7.41, which puts the current rally into sharp focus.

In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $4.5 million, earnings will come to $736.4 thousand, and it would be trading on a PE ratio of 1392.3x, assuming you use a discount rate of 7.0%.

Curious how Absci gets to that kind of valuation multiple on relatively modest projected earnings and revenue. The narrative leans heavily on ambitious growth, margin expansion and a high implied future P/E. Want to see how those moving parts fit together before you judge that fair value.

Result: Fair Value of $4.54 (OVERVALUED)

However, Absci’s story could change quickly if ABS-201 runs into safety or efficacy issues, or if expected pharma partnerships are slower to materialize than analysts model.

Another View on Absci’s Valuation

The narrative around Absci so far leans on future earnings and implied P/E multiples, but today investors can also look at its P/B ratio of 6.7x. That is below the peer average of 8.7x, yet well above the broader US biotech industry at 2.4x. This combination suggests both room for optimism and clear valuation risk if sentiment cools.

For a closer look at how this ratio based view lines up with other checks on Absci, have a read of the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of enthusiasm and concern around Absci feels familiar, use the data to move quickly and shape your own view with 1 key reward and 5 important warning signs

Looking for more investment ideas beyond Absci?

If Absci has sharpened your interest in focused stock picking, do not stop here. Broaden your watchlist now with a few targeted ideas that others may miss.

• Target potential value opportunities by scanning companies that look mispriced relative to quality using the 45 high quality undervalued stocks.
• Strengthen your income stream by focusing on businesses that combine higher yields with resilience through the 8 dividend fortresses.
• Reduce portfolio stress by concentrating on companies with lower risk profiles using the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.